{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036822","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.511558+00:00","generated_at":"2026-06-04T07:18:32.121864+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash","bullets":["One-time $8M payment from Novartis for rights to Beovu and another asset royalties.","All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.","Non-dilutive capital to support lead ADC asset PYX-201 development.","Pyxis retains rights to three other antibodies from Apexigen licensees.","$8M payment to be recorded in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036822","json":"https://secwatch.observer/filing/0000950170-24-036822.json","markdown":"https://secwatch.observer/filing/0000950170-24-036822.md","text":"https://secwatch.observer/filing/0000950170-24-036822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/0000950170-24-036822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/pyxs-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:18:32.121864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}